SF3B1 and myelodysplastic syndrome: Unfortunately, molecular data were insufficient to evaluate whether mutations defined in the IPSS-M as having poor prognosis in patients with MDS-SF3B1 have the same impact in cases with CMML-SF3B1 (34).